Tolka AI Therapeutics develops personalized bacteriophage therapies for antibiotic-resistant infections such as Mycobacterium abscessus complex pulmonary disease. The company combines agentic AI, robotic manufacturing, and bacteriophages to create patient-specific treatments through its SWIFT platform. It operates an expanded access program for physicians treating MABC-PD and is led by cofounder and CEO Johan Wikstrom.